KM Research Hub

FIXED FIVE-YEAR COHORT AUDIT

近五年文献重新检索与对照

旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。

complete · complete 汇总 CSV 明细 CSV
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1

四个独立队列

数字为批次中保存的原始 PMID 数,不会随着日常监测改变。

历史库存参照组 13065 audit_reference · server-inventory-snapshot-v1
旧查询复现组 7069 primary_legacy · legacy-phase3-fulltext-v1
严格 v3 主组 4707 primary_new · oncology-phase3-survival-strict-v3
v3 广召回影子组 13640 recall_audit · oncology-phase3-survival-discovery-v3

集合关系

交集和差集均按 PMID 精确计算;DOI 只用于明细核对。

比较交集左组独有右组独有
历史库存 ↔ 旧查询复现 7028 6037 41
旧查询复现 ↔ 严格 v3 2464 4605 2243
严格 v3 ↔ 广召回影子组 4707 0 8933
严格查询未命中、但影子组经 v3 筛选后合格 166 篇

元数据入排

20925 / 20925 已完成

KM 证据

仅检查 v3 元数据合格论文,不运行曲线数字化。

论文明细

共 17654 篇;可组合筛选集合关系、入排结果和 KM 证据。

论文队列集合关系v3 入排KM 证据
Immune-Enhancing Nutrition and Outcomes After Radical Cystectomy: A Randomized Clinical Trial. PMID 42475098 · JAMA Netw Open · 2026-Jul-01 The trial is an original Phase III randomized study in human bladder cancer with time-to-event endpoints (OS, DFS). However, the intervention is a specialized oral nutrition formula (immunonutrition) and not a drug, which fails the required drug-intervention criterion.
H L S B
旧组与严格 v3 交集 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Concurrent chemoradiotherapy with or without simultaneous integrated boost for unresectable stage III non-small-cell lung cancer: a randomized phase II trial with exploratory EGFR and PD-L1 analyses. PMID 42456525 · Cancer Genet · 2026-Jul-01 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Treatment Satisfaction, Improvements in Jawline Definition, and Psychosocial Impact With OnabotulinumtoxinA for Platysma Prominence: Patient-Reported Outcomes From 2 Multicenter, Randomized, Placebo-Controlled Phase 3 Studies. PMID 42400884 · Aesthet Surg J · 2026-Jul-01 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Neoadjuvant Chemotherapy in Resectable Colon Cancer: Evidence, Controversies, and an Implementation Roadmap for 2026. PMID 42390664 · Ann Surg Oncol · 2026-Jul-01 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Evaluation and analysis of renal injury in patients with advanced renal cell carcinoma receiving first-line benmelstobart plus anlotinib: results from the ETER100 study. PMID 42387482 · BMC Med · 2026-Jul-01 The report is an original, randomized, oncology trial with a drug intervention and time-to-event endpoints, but it is a secondary analysis (renal injury) rather than the primary or key secondary efficacy analysis of the trial. Additionally, the trial phase is not explicitly confirmed as Phase III/IIIb or Phase II/III in the provided information.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Early Response to Calcipotriol and Betamethasone Dipropionate PAD-Cream at Week 4 in Patients with Mild-to-Moderate Plaque Psoriasis: A Post-Hoc Pooled Analysis of Two Phase III Trials. PMID 42387164 · Dermatol Ther (Heidelb) · 2026-Jul-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H
仅历史库存 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Safety and immunogenicity of concomitant quadrivalent meningococcus ACYW-TT and meningococcus group B vaccines. PMID 42386770 · NPJ Vaccines · 2026-Jul-01 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Robotic versus Open Pancreatoduodenectomy (PORTAL): multicentre, single masked, phase 3, non-inferiority randomised controlled trial. PMID 42386316 · BMJ · 2026-Jul-01 The trial is a Phase III randomized trial in oncology (pancreatic cancer) but does not meet the required criteria for a drug-containing intervention or a primary/key secondary time-to-event efficacy endpoint (OS, PFS, etc.). The intervention is purely surgical, and the primary endpoint is a composite measure of postoperative functional recovery, not a Kaplan-Meier-analyzed survival or progression metric.
H L S B
旧组与严格 v3 交集 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Bimekizumab Improves Health Status and Work Productivity, With Reduced Productivity Costs, to 3 Years in Axial Spondyloarthritis and Psoriatic Arthritis. PMID 42386286 · J Rheumatol · 2026-Jul-01 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Reply to Comment on "Clazakizumab in the treatment of chronic active antibody-mediated kidney transplant rejection: Results from the IMAGINE phase 3, randomized, double-blind, placebo-controlled study". PMID 42385844 · Am J Transplant · 2026-Jul-01 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H
仅历史库存 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Neoadjuvant toripalimab plus celecoxib versus toripalimab monotherapy for mismatch repair-deficient or microsatellite instability-high, locally advanced colorectal cancer (PICC-2): an open-label, multicentre, randomised, phase 2 trial. PMID 42385761 · Lancet Oncol · 2026-Jul-01 The trial is a Phase II study with a primary endpoint of pathological complete response, which is not a time-to-event efficacy endpoint. No Kaplan-Meier or hazard ratio data for OS, PFS, DFS, EFS, RFS, or TTP are reported.
H B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Updated patient-reported outcomes and the effect of disease progression on health-related quality of life in the PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer. PMID 42385609 · Gynecol Oncol · 2026-Jul-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Baseline value and longitudinal kinetics of circulating nucleosomes during neo-adjuvant chemotherapy in newly diagnosed ovarian cancer: Results from a GINECO/GINEGEPS study of the randomized phase II CHIVA trial. PMID 42385345 · Transl Oncol · 2026-Jul-01 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
From Cardioprotection to Trial Design: Rethinking Cardiac Safety in Oncology. PMID 42384221 · Curr Heart Fail Rep · 2026-Jul-01 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Impact of Fostamatinib on Inflammatory Biomarkers in Hospitalized Patients With COVID-19. PMID 42329789 · Crit Care Explor · 2026-Jul-01 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Patient-reported outcomes in castration-resistant prostate cancer with bone metastases treated with radium-223 with or without olaparib. PMID 42319132 · Cancer · 2026-Jul-01 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Systemic radionuclide treatments in gastro-entero-pancreatic neuroendocrine tumours. PMID 42240214 · Curr Opin Oncol · 2026-Jul-01 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Finerenone Across Cardiovascular-Kidney-Metabolic Syndrome Stages: Post Hoc Analysis of the FIDELITY Randomized Clinical Trials. PMID 42234437 · JAMA Cardiol · 2026-Jul-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Effects of a trans-theoretical model-based structured psychoeducational continuing care program in adult patients with acute Leukemia. PMID 42224028 · Physiol Int · 2026-Jul-01 The study is a randomized oncology trial reporting overall survival as a time-to-event endpoint. However, it is ineligible because it does not include a drug-containing intervention (the intervention is a psychoeducational program) and the formal trial phase (III/IIIb or II/III) is not established in the provided metadata.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Efficacy and Safety of Ecopipam for Tourette Syndrome: A Phase 3 Randomized Clinical Trial. PMID 42189524 · JAMA Neurol · 2026-Jul-01 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Aroxybutynin and atomoxetine (AD109) for obstructive sleep apnea: a randomized phase 3 trial (SynAIRgy). PMID 42148495 · Am J Respir Crit Care Med · 2026-Jul-01 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Ixekizumab With or Without Tirzepatide in Adults With Psoriasis and Overweight or Obesity: A Phase 3b Randomized Clinical Trial. PMID 42139049 · JAMA Dermatol · 2026-Jul-01 未发现恶性肿瘤人群证据。
L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Testosterone Treatment in Prostate Cancer Survivors With Hypogonadism: A Randomized Clinical Trial. PMID 42113507 · JAMA Intern Med · 2026-Jul-01 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Sentinel Lymph Node Biopsy for Patients With cN1 HR+/HER2- Breast Cancer and Palpable Adenopathy: A Nonrandomized Clinical Trial. PMID 42090164 · JAMA Surg · 2026-Jul-01 The study is a nonrandomized clinical trial evaluating a surgical procedure (SLNB) for breast cancer. It is not a randomized trial, is not Phase III (it is a feasibility study), and lacks a drug intervention or a primary time-to-event efficacy endpoint as defined (e.g., OS, PFS).
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Randomized, Double-Blind, Placebo-Controlled Trial of Meriva (Curcuminoids) as a Candidate Chemoprevention Agent for Gastric Carcinogenesis. PMID 42077070 · Cancer Prev Res (Phila) · 2026-Jul-01 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Dosimetry Analysis of 177Lu-PSMA-I&T in Patients with Low-Volume Oligometastatic Hormone-Sensitive Prostate Cancer: A Secondary Analysis of the LUNAR Trial. PMID 41927282 · J Nucl Med · 2026-Jul-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
The Randomized Phase II ARC-9 Study of Etrumadenant-Based Therapy versus Regorafenib in Patients with Previously Treated Metastatic Colorectal Cancer. PMID 41870279 · Clin Cancer Res · 2026-Jul-01 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Endoscopic Application of Tranexamic Acid and Sucralfate in Upper Gastrointestinal Bleeding: A Randomized Controlled Trial. PMID 41860133 · Clin Transl Gastroenterol · 2026-Jul-01 The study is a randomized trial of drug interventions (tranexamic acid and sucralfate) for upper gastrointestinal bleeding, but it is not an oncology study. The primary endpoint is rebleeding rate, a binary outcome, not a time-to-event efficacy endpoint like OS, PFS, DFS, EFS, RFS, or TTP.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Efficacy and Safety of Remimazolam Tosylate versus Propofol for Sedation of Postoperative Mechanically Ventilated Patients in Intensive Care Units: A Multicenter, Randomized, Single-blind, Noninferiority, Phase 3 Trial. PMID 41855428 · Anesthesiology · 2026-Jul-01 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Recovery of response and long-term outcomes following loss of response and dose escalation of subcutaneous infliximab: a post hoc analysis of the LIBERTY-CD & LIBERTY-UC trials. PMID 41849243 · Inflamm Bowel Dis · 2026-Jul-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
The Effect of Preoperative Tranexamic Acid on Blood Transfusions in Geriatric Hip Fracture Surgery: A Randomized Controlled Trial. PMID 41837612 · J Orthop Trauma · 2026-Jul-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Adjuvant Chemotherapy After Curative Intent Resection of Ampullary Cancer (ADAPTA): Study Protocol for a Pan-European Prospective Multicenter Double Single Arm Trial. PMID 41812337 · Am J Clin Oncol · 2026-Jul-01 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Safety and Efficacy of Eflornithine in Patients with Gastric Precancerous Lesions: A Double-Blinded, Randomized Clinical Trial. PMID 41801147 · Cancer Prev Res (Phila) · 2026-Jul-01 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Depression severity and efficacy outcomes: post hoc analyses from a phase 3 trial of esmethadone for the adjunctive treatment of major depressive disorder with inadequate response to standard antidepressants. PMID 41749468 · Int Clin Psychopharmacol · 2026-Jul-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Pelacarsen and lipoprotein(a) apheresis in secondary prevention: the Lp(a)FRONTIERS APHERESIS trial. PMID 41721795 · Eur Heart J · 2026-Jul-01 未发现恶性肿瘤人群证据。
L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Tamoxifen therapy benefit in luminal A and B breast cancer with 20-year follow-up. PMID 41712503 · J Natl Cancer Inst · 2026-Jul-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Clonal Hematopoiesis after 177Lu-PSMA-617 Radioligand Therapy in Prostate Cancer. PMID 41649873 · Clin Cancer Res · 2026-Jul-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Inclisiran in Patients with CKD: Post Hoc Pooled Analysis of Three Phase 3 Trials. PMID 41604274 · J Am Soc Nephrol · 2026-Jul-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Imetelstat improves patient-reported outcomes and quality of life in lower-risk myelodysplastic syndromes: results from the phase III IMerge study. PMID 41568521 · Haematologica · 2026-Jul-01 The study is an oncology Phase III randomized trial with a drug intervention and presents original results. However, the primary endpoint of the IMerge study is 8-week RBC transfusion independence (a categorical response endpoint), not a time-to-event outcome like OS, PFS, DFS, etc. This specific report focuses on secondary/quality-of-life analyses (patient-reported outcomes), which are excluded per the criteria. There is no mention of Kaplan-Meier curves or hazard ratios for a time-to-event endpoint in this abstract.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Clinical Trial Endpoints for Perianal Fistulizing Crohn's Disease. PMID 41504318 · Am J Gastroenterol · 2026-Jul-01 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H
仅历史库存 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Precision in Practice: A Critical Overview of Recent Advances in Nasopharyngeal Cancer Management. PMID 41365475 · Int J Radiat Oncol Biol Phys · 2026-Jul-01 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Progression of Dupuytren Contracture: A Randomized Controlled Trial Comparing Surgery, Needle Fasciotomy, and Collagenase Injection. PMID 41334972 · Plast Reconstr Surg · 2026-Jul-01 未发现恶性肿瘤人群证据。
B
仅广召回影子组 excludednon_oncology pending 0 Figure · 0 Panel · risk -
OnabotulinumtoxinA for Platysma Prominence: Safety and Efficacy Results from a Phase 3 Open-Label Repeat Treatment Study. PMID 41329600 · Plast Reconstr Surg · 2026-Jul-01 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Effects of Nutritional Interventions on Quality of Life in Patients with Nasopharyngeal Carcinoma Undergoing Radiation Therapy Based on Dynamic Nutritional Risk Screening and Assessment: An Open-Label Single-Center Randomized Phase 3 Trial. PMID 41325872 · Int J Radiat Oncol Biol Phys · 2026-Jul-01 The study is a randomized, Phase III trial in oncology patients, but it evaluates nutritional interventions (not a drug-containing intervention) and uses quality-of-life and nutritional status as endpoints, not a time-to-event efficacy endpoint (e.g., OS, PFS, DFS).
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Combination of Neuronavigation-Guided Focused Ultrasound and Bevacizumab for Patients With Recurrent Glioblastoma: A Pilot Study. PMID 41283685 · Neurosurgery · 2026-Jul-01 The record describes a single-arm, open-label pilot study, not a randomized trial. It is explicitly labeled as a 'pilot trial' and does not report Phase III/IIIb or Phase II/III evidence. While it is an oncology study with a drug intervention and a primary time-to-event endpoint (PFS), it fails the critical eligibility criteria for being a randomized Phase III/IIIb or Phase II/III trial.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Factors Associated With Perfluorohexyloctane Treatment Response in Dry Eye Disease Associated With Meibomian Gland Dysfunction. PMID 40632907 · Cornea · 2026-Jul-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Clinical trials in cancer theranostics with potential near-term impact on clinical practice. PMID 39873742 · Br J Radiol · 2026-Jul-01 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Postoperative Exercise Training in Patients With Colorectal Liver Metastases: A Randomized Controlled Trial. PMID 39523954 · Ann Surg · 2026-Jul-01 The trial is a randomized, oncology study in humans evaluating postoperative exercise in colorectal liver metastases patients receiving chemotherapy. It reports primary safety outcomes and secondary efficacy/quality-of-life endpoints. However, it does not meet the core eligibility criteria: it is not explicitly a Phase III or definitive drug efficacy trial (the phase is not stated, and the focus is exercise intervention, not a specific drug regimen), and no time-to-event efficacy endpoint (like OS or PFS) is reported as primary or key secondary. The primary endpoint is safety (serious adverse events).
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Exploratory Time-Dependent Patterns in Estimated Treatment Effect of Talazoparib Plus Enzalutamide in HRR Non-Deficient or Unknown Metastatic Castration-Resistant Prostate Cancer: A Post Hoc Analysis of the TALAPRO-2 Trial. PMID 42502892 · Int J Urol · 2026-Jul 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Population Pharmacokinetic Modeling for the Iminosugar Lucerastat Supports Dose Adaptation in Patients With Fabry Disease and Moderate to Severe Renal Function Impairment. PMID 42473895 · J Clin Pharmacol · 2026-Jul 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -